Pomalidomide plus low-dose dexamethasone versus high-dose dexamethasone alone for patients with relapsed and refractory multiple myeloma (MM-003): a randomised, open-label, phase 3 trial.
about
Salvage therapies in relapsed and/or refractory myeloma: what is current and what is the future?Current Trends of Renal Impairment in Multiple MyelomaCarfilzomib/pomalidomide single-agent or in combination with other agents for the management of relapsed/refractory multiple myeloma : a meta-analysis of 37 trialsNovel agents in the treatment of multiple myeloma: a review about the futureFirst line vs delayed transplantation in myeloma: Certainties and controversiesTreatment of relapsed and refractory multiple myelomaMonoclonal antibodies targeting CD38 in hematological malignancies and beyondEvolving paradigms in the treatment of relapsed/refractory multiple myeloma: increased options and increased complexityPomalidomideAmerican Society of Blood and Marrow Transplantation, European Society of Blood and Marrow Transplantation, Blood and Marrow Transplant Clinical Trials Network, and International Myeloma Working Group Consensus Conference on Salvage Hematopoietic CePotential role of daratumumab in the treatment of multiple myelomaMultiple myeloma: 2014 Update on diagnosis, risk-stratification, and managementEuropean perspective on multiple myeloma treatment strategies in 2014Evolving Paradigms in the Management of Multiple Myeloma: Novel Agents and Targeted TherapiesThe Danish National Multiple Myeloma RegistryThe Role of Panobinostat Plus Bortezomib and Dexamethasone in Treating Relapsed or Relapsed and Refractory Multiple Myeloma: A European PerspectiveRecent advances in understanding multiple myelomaNew investigational drugs with single-agent activity in multiple myelomaRecent advances in multiple myeloma: a Korean perspectiveThe European medicines agency review of pomalidomide in combination with low-dose dexamethasone for the treatment of adult patients with multiple myeloma: summary of the scientific assessment of the committee for medicinal products for human useCarfilzomib and pomalidomide in patients with relapsed and/or refractory multiple myeloma with baseline risk factorsTriplet combinations in relapsed/refractory myeloma: update on recent phase 3 trials.Renal Toxicities of Novel Agents Used for Treatment of Multiple Myeloma.Pomalidomide for the treatment of relapsed-refractory multiple myeloma: a review of biological and clinical data.Treatment of multiple myeloma bone disease: experimental and clinical data.Analysis of Real-World Data on Overall Survival in Multiple Myeloma Patients With ≥3 Prior Lines of Therapy Including a Proteasome Inhibitor (PI) and an Immunomodulatory Drug (IMiD), or Double Refractory to a PI and an IMiD.Expert panel consensus statement on the optimal use of pomalidomide in relapsed and refractory multiple myelomaImpact of pomalidomide therapy in multiple myeloma: a recent survey.Bendamustine in combination with thalidomide and dexamethasone is a viable salvage option in myeloma relapsed and/or refractory to bortezomib and lenalidomide.Panobinostat plus bortezomib and dexamethasone in previously treated multiple myeloma: outcomes by prior treatmentVenous thromboembolism in hematopoietic stem cell transplant recipients.A multicenter phase 2 study of pomalidomide plus dexamethasone in patients with relapsed and refractory multiple myeloma: the Japanese MM-011 trialSafety and efficacy of pomalidomide plus low-dose dexamethasone in STRATUS (MM-010): a phase 3b study in refractory multiple myelomaBendamustine, lenalidomide and dexamethasone (BRd) has high activity as 2nd -line therapy for relapsed and refractory multiple myeloma - a phase II trial.Real-world use of pomalidomide and dexamethasone in double refractory multiple myeloma suggests benefit in renal impairment and adverse genetics: a multi-centre UK experience.Systematic review and meta-analysis of the efficacy and safety of novel monoclonal antibodies for treatment of relapsed/refractory multiple myeloma.Adverse event management in patients with relapsed and refractory multiple myeloma taking pomalidomide plus low-dose dexamethasone: A pooled analysis.Pomalidomide, bortezomib and low-dose dexamethasone in lenalidomide-refractory and proteasome inhibitor-exposed myeloma.Pomalidomide, Bortezomib and Dexamethasone (PVD) for Patients with Relapsed, Lenalidomide Refractory Multiple Myeloma.Optimizing current and emerging therapies in multiple myeloma: a guide for the hematologist.
P2860
Q26740359-F46A6571-9F08-453E-A042-D13E3B922909Q26740444-92C806C5-F9D1-4F7D-8258-D0755A8CF18BQ26741620-28168ACB-AAD1-46C0-BE09-9CDD522BA503Q26745924-AC767392-3E31-463A-8C93-A316B7E8B4E2Q26745957-6C6A2F2D-50C1-4E27-B16F-48C92B7D7205Q26749180-A7C1B59D-670B-4832-B6E7-3EB6FF5B2117Q26766718-0F33D2D9-7A70-4753-807D-2D4567B03F18Q26771331-7F42BB50-F6C2-479D-B697-E2A679DD7026Q26773342-108B0C60-8704-4FC3-94CE-837E542B1206Q26782868-1EBE3EAD-195A-4FDF-BA5F-49EBFE301BFEQ26824157-98A5CBBC-A442-4F54-B76F-A506E4886318Q26998884-9A7C2576-A8DC-4371-9D17-5EC3063597FFQ27005966-5223A19B-1FC9-4680-8BB7-44FB6E084168Q27026478-5EA33E63-AA8E-472E-AE02-EAEDAD15961FQ28067187-24D0E3B1-DA4E-4915-A920-33F537FD35E1Q28069789-F122EE5F-C3B9-4CF8-B825-DDA3A939A2CBQ28070331-8C3B75B2-B6B9-4E18-AD57-410F3A59C0E3Q28071551-42F8764A-D20B-4F1D-BD1A-963989E2F611Q28074521-EBC4E782-1A02-4E21-AF49-9C3DE9F1FD2AQ28084478-952017D5-DF33-4C6C-AEA7-AEE0BFF8FD5EQ28084683-73603565-8D91-403D-9A8E-F6336C240CB8Q30238893-1D62385C-B4AF-407B-9CD8-98980E887717Q30275870-3A1B2D72-1D66-4FCA-82D9-6FA81C0E6DA4Q30802505-CBD62AC2-35FD-43CD-900D-7890442E347CQ30868833-EBA5D52F-3803-47E0-B300-EB25B68F7EC3Q31119290-87924D99-F092-4507-97C9-2502084954A8Q33413142-C1A180A8-9046-47E2-A6B2-DC575B096D5FQ33416346-282D1478-FFF6-43D5-80BC-C3429B80267CQ33418389-56621B40-7B6A-4F46-BE63-9F55C5F13944Q33428098-9CABC520-3ABF-4AFB-8882-9CA341697080Q33428591-78B00FFB-57EB-4F0A-8FE8-39137D7CB20AQ33431621-E9BF3E59-E82F-476F-B425-C3387D6510C2Q33432492-AB9AC00F-C9C8-4C60-8CEE-A7D5BF951AF7Q33437691-19BBF9FB-5202-40B1-8693-A801862FF07EQ33439437-B53D1A09-8465-446B-B6F2-22FB94D9DFC3Q33441476-E0EC2C8F-9C5D-4365-8F79-4B3642FDFD54Q33441845-88141815-5856-4320-A083-42165A32CDC7Q33442923-19EB8F37-165B-4A84-862E-2C21D3BC6564Q33443411-541F8E0B-2EFB-4CC5-908D-4A4448344C0BQ34551324-A0458701-8A2B-4C36-915A-D5C7494447C7
P2860
Pomalidomide plus low-dose dexamethasone versus high-dose dexamethasone alone for patients with relapsed and refractory multiple myeloma (MM-003): a randomised, open-label, phase 3 trial.
description
2013 nî lūn-bûn
@nan
2013 թուականի Սեպտեմբերին հրատարակուած գիտական յօդուած
@hyw
2013 թվականի սեպտեմբերին հրատարակված գիտական հոդված
@hy
2013年の論文
@ja
2013年論文
@yue
2013年論文
@zh-hant
2013年論文
@zh-hk
2013年論文
@zh-mo
2013年論文
@zh-tw
2013年论文
@wuu
name
Pomalidomide plus low-dose dex ...... ed, open-label, phase 3 trial.
@ast
Pomalidomide plus low-dose dex ...... ed, open-label, phase 3 trial.
@en
type
label
Pomalidomide plus low-dose dex ...... ed, open-label, phase 3 trial.
@ast
Pomalidomide plus low-dose dex ...... ed, open-label, phase 3 trial.
@en
prefLabel
Pomalidomide plus low-dose dex ...... ed, open-label, phase 3 trial.
@ast
Pomalidomide plus low-dose dex ...... ed, open-label, phase 3 trial.
@en
P2093
P50
P1433
P1476
Pomalidomide plus low-dose dex ...... ed, open-label, phase 3 trial.
@en
P2093
Adrian Alegre
Andrew Belch
Anne Banos
Christian Jacques
Christine Chen
Joaquin Martinez-Lopez
Kevin Song
Lars Sternas
Laurent Garderet
Lionel Karlin
P304
P356
10.1016/S1470-2045(13)70380-2
P50
P577
2013-09-03T00:00:00Z